01

Upadacitinib Beats Nemolizumab on EASI-75 and Itch in Indirect AD Analysis

Placebo-adjusted EASI-75 gains of 40.8–51.8 points for upadacitinib vs 13.4 for nemolizumab at Week 16 in an AbbVie-funded MAIC presented at EADV 2026.